Novel th1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same

Abstract

The present invention provides the induction of novel Th1 response, the induction of cytotoxic T cells and anti-cancer/anti-allergic activity techniques. Provided is a combination of a CpG oligonucleotide and an STING agonist. Also provided is a composition which contains an STING agonist, can be used as a type-I adjuvant, and is characterized in that the STING agonist is administered together with a CpG oligonucleotide.Further provided is an anti-cancer agent comprising a CpG oligonucleotide and is characterized in that the CpG oligonucleotide is administered together with an STING agonist. Still further provided is a composition which contains a CpG oligonucleotide and can be used for reducing or eliminating the IgE-inducing activity of an STING agonist.

1 . A method of reducing or eliminating a type II immune response and expressing or enhancing a type I immune response; exerting a type I adjuvant effect of a STING agonist; or enhancing action of a type I adjuvant of a CpG oligonucleotide consisting essentially of administering an effective amount of a CpG oligonucleotide and an effective amount of a STING agonist to the subject. 
     
     
         2 . The method of  claim 1 , wherein the method is for treating cancer or providing prevention of cancer to a subject. 
     
     
         3 . The method of  claim 1 , wherein the cancer is selected from lymphoma and melanoma. 
     
     
         4 . The method of  claim 1 , wherein the treatment or prevention is achieved by inducing interferon γ (IFN-γ). 
     
     
         5 . The method of  claim 1 , wherein the treatment or prevention is achieved by a vaccine adjuvant. 
     
     
         6 . The method of  claim 1 , wherein the treatment or prevention is achieved by reducing or eliminating IgE inducing action of a STING agonist. 
     
     
         7 . The method of  claim 1 , wherein the CpG oligonucleotide is a type K/B oligonucleotide. 
     
     
         8 . The method of  claim 1 , wherein the CpG oligonucleotide is a CpG oligonucleotide selected from the group consisting of K3 CpG (SEQ ID NO: 1), CpG 1826 (SEQ ID NO: 2), and D35 CpG (SEQ ID NO: 3). 
     
     
         9 . The method of  claim 1 , wherein the STING agonist is a STING agonist selected from cGAMP, 3′3′-cGAMP, c-di-GAMP, c-di-AMP, 2′3′-cGAMP, and DMXAA. 
     
     
         10 . A combination comprising a STING agonist and a CpG oligonucleotide, wherein the CpG oligonucleotide is a CpG oligonucleotide selected from the group consisting of K3 CpG (SEQ ID NO: 1), CpG 1826 (SEQ ID NO: 2), and D35 CpG (SEQ ID NO: 3). 
     
     
         11 . The combination of  claim 9 , wherein the STING agonist is a STING agonist selected from cGAMP, 3′3′-cGAMP, c-di-GAMP, c-di-AMP, 2′3′-cGAMP, and DMXAA.